Literature DB >> 14514648

Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

Jonathan Q Purnell1, Raj K Dev, Michael W Steffes, Patricia A Cleary, Jerry P Palmer, Irl B Hirsch, John E Hokanson, John D Brunzell.   

Abstract

Intensive therapy for type 1 diabetes results in greater weight gain than conventional therapy. Many factors may predispose to this greater weight gain, including improved glycemic control, genetic susceptibility to obesity, and hypoglycemia. To study this, relationships among family history of type 2 diabetes, frequency of severe hypoglycemia, beta-cell autoantibodies, and weight gain were examined in 1,168 subjects aged > or =18 years at baseline randomized to intensive and conventional therapy groups in the Diabetes Control and Complications Trial. With intensive therapy, subjects with a family history of type 2 diabetes had greater central weight gain and dyslipidemia characterized by higher triglyceride levels and greater cholesterol in VLDLs and intermediate-density lipoproteins compared with subjects with no family history. Neither the frequency of severe hypoglycemia nor positivity to GAD65 and insulinoma-associated protein 2 antibodies was associated with increased weight gain with either intensive or conventional therapy. These data support the hypothesis that increased weight gain with intensive therapy might be explained, in part, by genetic traits.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514648      PMCID: PMC2632607          DOI: 10.2337/diabetes.52.10.2623

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  42 in total

1.  Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes.

Authors:  R R Wing; R Klein; S E Moss
Journal:  Diabetes Care       Date:  1990-11       Impact factor: 19.112

2.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

3.  Features of syndrome X in first-degree relatives of NIDDM patients.

Authors:  M W Stewart; D B Humphriss; T S Berrish; L A Barriocanal; L R Trajano; K G Alberti; M Walker
Journal:  Diabetes Care       Date:  1995-07       Impact factor: 19.112

4.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

5.  Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

6.  Insulin resistance in offspring of hypertensive parents.

Authors:  O L Beatty; R Harper; B Sheridan; A B Atkinson; P M Bell
Journal:  BMJ       Date:  1993-07-10

7.  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.

Authors: 
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

8.  Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease.

Authors:  T Tuomi; L C Groop; P Z Zimmet; M J Rowley; W Knowles; I R Mackay
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

9.  Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type.

Authors:  W A Hagopian; A E Karlsen; A Gottsäter; M Landin-Olsson; C E Grubin; G Sundkvist; J S Petersen; E Boel; T Dyrberg; A Lernmark
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents.

Authors:  G Gulli; E Ferrannini; M Stern; S Haffner; R A DeFronzo
Journal:  Diabetes       Date:  1992-12       Impact factor: 9.461

View more
  27 in total

1.  Diabetes in the young but not needing insulin--what type is it?

Authors:  Umesh Dashora; Rachael Golton; Amanda Combes; Sathis Kumar
Journal:  BMJ Case Rep       Date:  2012-01-10

2.  Changes in socio-economic status and lipoproteins in Chilean adolescents: a 16-year longitudinal study.

Authors:  Zachary J Madewell; Estela Blanco; Raquel Burrows; Betsy Lozoff; Sheila Gahagan
Journal:  Public Health Nutr       Date:  2018-11-26       Impact factor: 4.022

3.  Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes.

Authors:  D M Maahs; K Nadeau; J K Snell-Bergeon; I Schauer; B Bergman; N A West; M Rewers; S R Daniels; L G Ogden; R F Hamman; D Dabelea
Journal:  Diabet Med       Date:  2011-02       Impact factor: 4.359

4.  Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice.

Authors:  J Yoon; S Subramanian; Y Ding; S Wang; L Goodspeed; B Sullivan; J Kim; K D O'Brien; A Chait
Journal:  Diabetologia       Date:  2011-02-17       Impact factor: 10.122

5.  Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study.

Authors:  Ian H de Boer; Shalamar D Sibley; Bryan Kestenbaum; Joshua N Sampson; Bessie Young; Patricia A Cleary; Michael W Steffes; Noel S Weiss; John D Brunzell
Journal:  J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 10.121

Review 6.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 7.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

8.  Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance.

Authors:  David M Maahs; John E Hokanson; Hong Wang; Gregory L Kinney; Janet K Snell-Bergeon; Ashley East; Bryan C Bergman; Irene E Schauer; Marian Rewers; Robert H Eckel
Journal:  Diabetes       Date:  2010-04-14       Impact factor: 9.461

9.  The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.

Authors:  Jonathan Q Purnell; Bernard Zinman; John D Brunzell
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

10.  Effect of parental type 2 diabetes on offspring with type 1 diabetes.

Authors:  Lena M Thorn; Carol Forsblom; Johan Wadén; Jenny Söderlund; Milla Rosengård-Bärlund; Markku Saraheimo; Outi Heikkilä; Kustaa Hietala; Kim Pettersson-Fernholm; Jorma Ilonen; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2008-10-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.